The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells
Open accessAbstract
The repressive Hippo pathway has a profound tumour suppressive role in cancer by restraining the growth-promoting function of the transcriptional coactivator, YAP. We previously showed that the stem cell transcription factor Sox2 maintains cancer stem cells (CSCs) in osteosarcomas. We now report that in these tumours, Sox2 antagonizes the Hippo pathway by direct repression of two Hippo activators, Nf2 (Merlin) and WWC1 (Kibra), leading to exaggerated YAP function. Repression of Nf2, WWC1 and high YAP expression marks the CSC fraction of the tumor population, while the more differentiated fraction has high Nf2, high WWC1 and reduced YAP expression. YAP depletion sharply reduces CSCs and tumorigenicity of osteosarcomas. Thus, Sox2 interferes with the tumour-suppressive Hippo pathway to maintain CSCs in osteosarcomas. This Sox2-Hippo axis is conserved in other Sox2-dependent cancers such as glioblastomas. Disruption of YAP transcriptional activity could be a therapeutic strategy for Sox2-dependent tumours. Transcriptional regulators Sox2 and YAP maintain expression of stemness genes in normal and cancerous cells. Here the authors show that, in osteosarcomas, Sox2 activates YAP by directly repressing transcription of its upstream negative regulators Nf2 and WWC1, promoting cancer cell stemness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal
Zhao, B., Tumaneng, K., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2303 · Cited by 1,205
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
SOX2 Regulates YAP1 to Maintain Stemness and Determine Cell Fate in the Osteo-Adipo Lineage
Seo, E., Basu-Roy, U., Gunaratne, P. H., Coarfa, C., Lim, D.-S., Basilico, C., & Mansukhani, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.029 · Cited by 216
Self-citationWang, S., Xia, P., Ye, B., Huang, G., Liu, J., & Fan, Z. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.10.005 · Cited by 209
A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies
Jia, S.-F., Worth, L. L., & Kleinerman, E. S. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006623001465 · Cited by 146
Cited by
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
The Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387
Intra-tumor heterogeneity from a cancer stem cell perspective
Prasetyanti, P. R., & Medema, J. P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0600-4 · Cited by 800
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
NAD+ metabolism, stemness, the immune response, and cancer
Navas, L. E., & Carnero, A. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00354-w · Cited by 517
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 326
Insights into new mechanisms and models of cancer stem cell multidrug resistance
Garcia-Mayea, Y., Mir, C., Masson, F., Paciucci, R., & LLeonart, M. E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.022 · Cited by 324
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Cancer stem cells in osteosarcoma
Brown, H. K., Tellez-Gabriel, M., & Heymann, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.019 · Cited by 303
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer
Noguchi, S., Saito, A., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113674 · Cited by 277
The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells
Gobbi, G., Donati, B., Do Valle, I. F., Reggiani, F., Torricelli, F., Remondini, D., Castellani, G., Ambrosetti, D. C., Ciarrocchi, A., & Sancisi, V. (2019) · Oncogene · doi:10.1038/s41388-019-0924-1 · Cited by 69
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Sattler, M., Mohanty, A., Kulkarni, P., & Salgia, R. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.10.001 · Cited by 54
Metadata
- Authors
- Basu-Roy, U., Bayin, N. S., Rattanakorn, K., Han, E., Placantonakis, D. G., Mansukhani, A., & Basilico, C.
- Venue
- Nature Communications
- Published
- 2015-04-02
- Volume
- 6
- Issue
- 1
- Pages
- 6411-6411
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2013935331
- Cited by
- 247
- References
- 7
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.